Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Prescribing of Torii’s Sublingual Cedar Pollinosis Treatment Cedartolen to be Restricted to Trained Doctors
The Pharmaceutical and Food Safety Bureau’s Evaluation and Licensing Division issued a notification to prefectures on January 17 regarding the use of Torii Pharmaceutical’s pollinosis treatment Cedartolen Sublingual Drop – Japanese Cedar Pollen 200 JAU/mL Bottle, 2,000 JAU/mL Bottle, 2,000…
To read the full story
Related Article
- Japan’s 1st Sublingual Immunotherapy Wins Approval: Torii
January 21, 2014
REGULATORY
- LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
- Senior LDP Lawmakers Call for “Net Plus” in FY2026 Fee, Drug Price Revisions
December 10, 2025
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…